It is now clear that depleting microglia, at least temporarily via CSF1R inhibitors, can be beneficial in mouse models of Alzheimer's disease, and therefore has clinical potential. The gene discussed is CSF1R; the disease is early-onset autosomal dominant Alzheimer disease.